Original articleThe mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study
Section snippets
Patients
All patients were seen in the outpatient clinics at the Stanford University Department of Dermatology in California between July 2004 and April 2010. The collection of plasma from patients with DM for the purposes of proteomic and antibody analysis was approved by the Stanford Institutional Review Board. The population from which plasma was collected represented approximately 80% of the total number of patients with DM seen during this time period. Patients were only included if they had a
Patient population
We collected plasma from 77 patients with DM seen at the outpatient dermatology clinic at Stanford University School of Medicine. The characteristics of these patients are shown in Table I. At the time of plasma harvesting, patients had a median global skin and muscle disease activity of moderate and mild, respectively, on a Likert scoring system, and the median muscle strength score was 130 (maximum 150). The percentage of patients taking systemic corticosteroids (median prednisone dosage 6
Discussion
Antibodies to MDA5 have been recently described to be specifically associated with DM.10, 11, 13 Originally termed “CADM-140,” MDA5 reactivity initially was described as marking a population of patients with DM that was “clinically amyopathic.”10, 11, 13 However, the definition of “clinically amyopathic” is not universally agreed upon. This designation was intended to identify patients with strictly no evidence of myositis based only on what the clinician can see in the examination room (eg,
References (41)
- et al.
Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity
Pharmacol Ther
(2009) Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects
Dermatol Clin
(2002)- et al.
The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis
Hum Pathol
(1996) - et al.
A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies
J Am Acad Dermatol
(2006) - et al.
Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases
Respir Med
(2007) - et al.
Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center
J Am Acad Dermatol
(2007) - et al.
Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression
Rheumatology (Oxford)
(2009) - et al.
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy
J Exp Med
(2005) - et al.
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis
Arthritis Rheum
(2007) - et al.
Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis
Br J Dermatol
(2004)
The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis
J Cutan Pathol
Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis
Clin Exp Dermatol
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups
Medicine (Baltimore)
Idiopathic inflammatory myopathy: autoantibody update
Curr Rheumatol Rep
Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies
Autoimmunity
The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody
Rheumatology (Oxford)
RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease
Arthritis Rheum
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis
Arthritis Rheum
Cutaneous deep necrosis with dermatomyositis: correlation with interstitial pneumonia
Eur J Dermatol
The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis
Arch Neurol
Cited by (439)
IFN-γ: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies
2023, Autoimmunity Reviews
Supported by the Scleroderma Research Foundation (Dr Chung), National Institutes of Health (NIH) RO1 R37-DE-12354 (Dr Rosen), and NIH RO1 AR-44684 (Dr Casciola-Rosen). We thank the Johns Hopkins University Rheumatic Diseases Research Core Center (P30-AR-053503) for assays.
Conflicts of interest: None declared.